Skip to content

Pharmaco-economical Study in Kidney Transplantation

Pharmaco-economical Study in Kidney Transplantation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01989832
Acronym
EPHEGREN
Enrollment
570
Registered
2013-11-21
Start date
2013-02-28
Completion date
2017-12-31
Last updated
2019-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplant

Keywords

cohort, pharmaco-economic, kidney, transplantation, quality of life

Brief summary

The prevalence of renal acute rejection in transplantation is reduced thanks to the optimized use of immunosuppressive drugs. However, graft survival at ten years has not improved since then; this may be explained in part by the toxicity of these drugs, viral infections, and other comorbidities (diabetes, cardiovascular diseases …). According to transplant center, strategies for the combination of immunosuppressive drugs are different, and probably involve a difference in the global cost of patient management. There is no recommendation in France to establish similar practices. EPHEGREN is an observational, prospective, multicentric, pharmacoeconomic study for the renal transplant patients.

Interventions

None listed

Sponsors

University Hospital, Limoges
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients in the first month of renal graft, or patients already included in an other epidemiological French study (EPIGREN) in the 0-6 month period * Men of women aged more than 18 years * Patients able to exercise in writing their informed and free consent to participate to the biological collection * Patients not opposing to collect their medical data * Patients registered with a social security system * Patients able to complete the questionnaires

Exclusion criteria

* Patients aged less than 18 years and patients under guardianship * Patients with a follow-up at another center other than those part of the study

Design outcomes

Primary

MeasureTime frame
Number of Death4 years

Secondary

MeasureTime frame
to examine nature, dose and exposure in immunosuppresseurs.4 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026